PANKU-BREAST01
What it tests: Izalontamab brengitecan (IZA-BREN) in previously treated unresectable locally advanced or metastatic HR+/HER2− breast cancer. Randomized phase 3 study.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.